Indication intelligence, analysis and sector perception

Sage Therapeutics (SAGE) gets FDA approval for Zulresso, a postpartum depression (severe depression after childbirth) therapy

March 19, 2019

SAGE closed down -$0.78 to $156.10 and is UP +$7.91 or 5.07% to $164.01 in the aftermarket Zulresso is designed to reduce depression symptoms by targeting receptors of the neurotransmitter known as GABA, helping restore the normal balance in the brain that is disrupted around the time of childbirth.

Regenerative Medicine Earnings Scorecard - Q4/18 - to date

March 16, 2019

Q4/18 financial results is a scorecard of  (AKA) earnings of 45 covered  companies   32 out of 45 ...   The current LPS (loss per share) or net income, cash positions i.e. "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status"  

Osiris Therapeutics to be acquired for $660 M or +$19 per share by Smith & Nephew

March 12, 2019

OSIR is up +$0.14 or +0.74% to $19.02 having closed at $18.88 This offer represents a 37% premium to its 90-day volume-weighted average stock price

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.